Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Peglispro vs Insulin Glargine in Insulin-Naïve T2DM
NCT02106364Phase 3Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2015
- Primary completion
- Nov 2015
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin peglispro in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Planned start Feb 2015; status: withdrawn.
02
Drugs
insulin peglispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02106364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106364.